ARGATROBAN Rx

Select the drug indication to add to your list

ARGATROBAN

Miscellaneous hematological agents
Only 4 drugs may be compared at once

Generic Name and Formulations:

Argatroban 100mg/mL; soln for IV infusion after dilution.

Company:

GlaxoSmithKline

Select therapeutic use:

Indications for ARGATROBAN:

Prophylaxis and treatment of thrombosis in heparin-induced thrombocytopenia (HIT) or in those with or at risk of HIT undergoing percutaneous coronary intervention (PCI).

Adult:

≥18yrs: HIT: Discontinue heparin and obtain baseline aPTT. Initially 2micrograms/kg per minute by continuous IV infusion; check aPTT 2 hrs after starting; titrate to 1.5–3x baseline aPTT (max 100seconds); max 10micrograms/kg per minute. PCI: initially 25micrograms/kg per minute by IV infusion, and 350micrograms/kg bolus by large bore IV line over 3–5minutes; titrate based on activated clotting time (ACT) to therapeutic ACT of 300–450seconds. For both: hepatic impairment: reduce dose (see literature).

Children:

<18yrs: not established.

Contraindications:

Overt major bleeding. Concomitant other parenteral anticoagulants.

Warnings/Precautions:

Increased bleeding risk (eg, unexpected decreases in hematocrit or BP, severe hypertension, recent lumbar puncture, spinal anesthesia, major surgery, bleeding disorders, GI lesions). Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions:

Increased risk of bleeding with thrombolytics (eg, t-PA, streptokinase), Vit. K antagonists (eg, warfarin), heparin, antiplatelets, GP IIb/IIIa blockers (eg, eptifibatide).

Pharmacological Class:

Anticoagulant.

Adverse Reactions:

Hemorrhagic events, chest pain, dyspnea, cough, hypotension, rash, fever, GI upset, cardiac arrest, ventricular tachycardia, others.

How Supplied:

Single-use vial (2.5mL)—1